Novo Nordisk A/S (NYSE:NVO)
| 152.79 Delayed Data As of Mar 24 |  +4.40 / +2.96%Today’s Change | 95.02 Today|||52-Week Range 153.64 | +12.89% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $237.9B |
Company Description
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Contact Information
Novo Nordisk A/S Novo Allé 1 Bagsværd Capital Region 2880 |
Employees
Shareholders
| Other institutional | 6.46% |
| Mutual fund holders | 1.75% |
| Individual stakeholders | -- |
Top Executives
| Lars Fruergaard Jørgensen | President & Chief Executive Officer |
| Maziar Mike Doustdar | Executive Vice President-International Operations |
| Karsten Munk Knudsen | Chief Financial Officer & Executive Vice President |
| Henrik Ehlers Wulff | Executive VP & Head-Information Technology |
| Stephen Gough | Global Chief Medical Officer |
